To include your compound in the COVID-19 Resource Center, submit it here.

Study evaluates cost-effectiveness of MS drugs

The use of disease-modifying therapies in the U.S. to treat multiple sclerosis (MS) for 10 years leads to modest health gains compared to best supportive care but

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE